Umeclidinium bromide

Umeclidinium bromide is a long-acting muscarinic antagonist (LAMA) used in the management of chronic obstructive pulmonary disease (COPD). It is marketed under the brand name Incruse Ellipta by GlaxoSmithKline.

Pharmacology

Umeclidinium bromide is a muscarinic receptor antagonist, which means it works by blocking the action of acetylcholine, a neurotransmitter that can cause bronchoconstriction. By blocking the action of acetylcholine, umeclidinium bromide helps to relax and open the airways, making it easier for people with COPD to breathe.

Clinical Use

Umeclidinium bromide is used as a maintenance treatment for COPD. It is not used to relieve sudden breathing problems and won't replace a rescue inhaler. The medication is usually inhaled once a day using a special inhaler device.

Side Effects

Common side effects of umeclidinium bromide include upper respiratory tract infection, stuffy or runny nose, cough, mouth and throat pain, joint pain, change in taste, and urinary tract infection. Serious side effects may include allergic reactions, new or worsening eye problems, and new or worsening urinary problems.

Interactions

Umeclidinium bromide may interact with other drugs that also block acetylcholine, such as other anticholinergics. It may also interact with certain drugs used for Parkinson's disease, depression, or other psychiatric or emotional conditions.

See Also

• Chronic obstructive pulmonary disease
• Muscarinic antagonist
• Acetylcholine
• GlaxoSmithKline

‎